PCSK9 and Hypercholesterolemia: This highlights a cardioprotective function of PCSK9 suppression in HFD, which conforms with the use of PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha) for treatment of patients with hypercholesterolaemia.